The role of GLP-1 in neuronal activity and neurodegeneration
In the analysis, the researchers assessed the outcomes of 26 randomized controlled trials comprising 15,491 participants with overweight or obesity
In most trial participants, these symptoms were transient and mild to moderate in severity , often resolving or diminishing as the body adjusted over the first four to eight weeks
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis
Eli Lillys orforglipron is the first oral non-peptide GLP-1 receptor agonist advancing in obesity and diabetes research
GLP-1 Medications for Weight Loss: Semaglutide, Tirzepatide, and Retatrutide Compared The landscape of obesity treatment has shifted dramatically over the past decade, thanks to a class of medications known as GLP-1 receptor agonists